drugset / Trial / NCT00000117

Intravenous Immunoglobulin Therapy in Optic Neuritis

NCT00000117 ↗

Phase 3 Completed National Eye Institute (NEI)
RandomizedDouble-blindTreatment

Summary

To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the time course of recovery following IVIg administration. If the reports of IVIg-associated clinical improvement occurring within 3 to 6 months following treatment can be confirmed, this would provide indirect evidence that IVIg may promote central nervous system (CNS) remyelination in optic neuritis and multiple sclerosis (MS).

Timeline

Start
1995-08
Primary completion
—
Completion
1997-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Gammimmune N Unknown 0.4 g/kg Intravenous

Indications